Candel Therapeutics Inc (CADL)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
Candel Therapeutics Inc delivered fourth quarter of 2022 operating loss of $-8.102 millions
Published Apr 02 2023
Goran Soko / CSIMarket.com Contributer
![closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
Underlining the fiscal interval ending December 31 2022 Candel Therapeutics Inc Losses have expanded at $-0.15 per share, relative to the earnings of $1.54 per share a year before quarter, In the preceding quarter the Biotechnology & Pharmaceuticals company realized $-0.30 per share. Revenues surged by 3.226 % from $0.03 millions in the preceding quarter, EPS improved from $-0.30 per share.
For the fiscal period closing December 31 2022 Candel Therapeutics Inc logged net shortfall of $-5.083 million, instead of net proceeds of $33.242 millions have achieved in the comparable quarter a year before.
Even more, the company claimed as well a shortfall of $-18.79 millions and for the fiscal period 2022, Revenues of $0.13 millions.
Biotechnology & Pharmaceuticals The company has decreased it's shortfall per share to $-0.65 from $-1.91 in the preceding fiscal year, while Revenue remained unchanged by 0 % from $0.13 millions a year before.
Candel Therapeutics Inc is expected to report next financial earnings on May 11, 2023.